12,372 trials
COVID-19
Primary: Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat (mITT) Population — 0.752; 6.888…
Hemophilia A or B With Inhibitors
Primary: Number of Participants With Any Treatment Emergent Adverse Event (TEAE) — 8; 7; 1; 4 Participants
Asthma
Primary: Exposure Adjusted Incidence Rates of AEs/SAEs — 49.62; 62.66; 47.15; 69.97 Patients with AEs per 100 person-years
Parkinson's Disease (Disorder)
Primary: Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) — 11.67; 11.72; -0.39; -0.97 hours/day — p=0.0194
HIV Infections
Primary: Incidence Rate of HIV-1 Infection Diagnosed After Enrollment (Concurrent With First Vaccination) Through 24 Months After Enrollment — 0.034; 0.033; 0.034; 0.033 events…
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at Week 12 — -24.7; -5.3; -23.3; -9.1 Percent change — p=<0.001
Type 1 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -0.28; -0.21 Percentage of HbA1c
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
HIV
Primary: Change in Global CFR — -.05 ratio
Photosensitive Epilepsy
Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001
Corticosteroid Refractory Acute Graft vs Host Disease
Primary: Overall Response Rate (ORR) at Day 28 — 62.3; 39.4 Percentage of participants — p=<.0001
Osteoarthritis of the Knee
Primary: To Assess the Efficacy and Safety of the Association of Glucosamine Sulphate 500 mg/Chondroitin Sulphate 400 mg (Eurofarma) in the Treatment of Osteoarthritis, Compared…
Hemophilia
Primary: Estimated Annualized Bleeding Rate (ABR) — 7.482; 2.908 episodes per participant per year — p==0.0008
Infant, Newborn · Infant, Small for Gestational Age · Infant, Extremely Low Birth Weight
Primary: Bayley Scales of Infant Development (BSID) Cognitive Composite Score — 80.7; 81.1 Score on a scale
Non-Small-Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR) — 5.59; 1.54; 5.45 Months — p=0.0528